Genmab — Oktober 2022
-
Måske, men med den analogi skulle Genmab allerede ved aflæggelse af årsrapport 2021 have indregnet en ansøgning af Epco i 2022 outlook og det harmonerer ikke med et forsigtighedsprincip eller kommunikationen fra Genmab/Abbvie, der først over sommeren fandt grundlag for en ansøgning i 22. Tiden må vise resultatet
-
congress.esgo
1392
Tisotumab Vedotin Combinations with Pembrolizumab or Carboplatin in Patients With Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT Cx8/GOG-3024/innovaTV205- Cervical cancer Domenica Lorusso Italy Oral poster session 3 , 28 Oct 15:45-16:45
-
EPCO....!
-
Tæller det som en god fredagsnyhed?
-
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-submissions-regulatory-applications-epcoritamab Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody
-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL) Forventet inden 31/12 -
En FDA ansøgning af Genmab mens EMA har accepteret Abbvie ansøgning
-
accepteret = "validated" - op til egen fortolkning
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind